U.S., Dec. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07307469) titled 'Compassionate Administration of ZVS101e Injection for Extended Treatment' on Dec. 14.
Brief Summary: To provide treatment options for the control group of subjects who completed the 52-week follow-up of the Phase III clinical trial (Protocol number: ZYA-2024-001) of ZVS101e in subjects with crystalline retinal degeneration (BCD).
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Patients With Bietti Crystalline Corneoretinal Dystrophy (Carrying Biallelic CYP4V2 Mutations)
Intervention:
DRUG: ZVS101e
ZVS101e is a recombinant adeno-associated virus serotype 8 (rAAV8) vector expressing human CYP4V2 protein
Rec...